MAP3K1 and prostate cancer: The findings of Maria et al. [30] showed that the expression of constitutively active MAP3K1 leads to the apoptosis of AR-positive cancer cells, and the reconstruction of the AR pathway makes prostate cancer cells sensitive to MAP3K1-induced apoptosis.